Notice of Technical Assistance Webinar for RFA-MH-24-150, "Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Clinical High Risk for Psychosis Clinical Trial Network (U01 Clinical Trial Required)"
Notice NOT-MH-23-365 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 20, 2023 Category: Research Source Type: funding
Single Source: Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Clinical Trial Data Processing, Analysis, and Coordination Center (U24 Clinical Trial Not Allowed)
Funding Opportunity RFA-MH-24-151 from the NIH Guide for Grants and Contracts. The goal of CTDPACC is to support the efforts of the CHR for Psychosis Clinical Trial Network in a 12-16 week Proof of Principle (PoP) trial. The Clinical High Risk for Psychosis Clinical Trial Data Processing, Analysis, and Coordination Center (CTDPACC) will provide executive management, direction, and overall coordination, including data processing and analysis to support the Clinical High Risk (CHR) for Psychosis Clinical Trial Network companion FOA. That Network validates the utility of drug development tools (biomarkers, algorithms, clin...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 12, 2023 Category: Research Source Type: funding
Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Clinical High Risk for Psychosis Clinical Trial Network (U01 Clinical Trial Required)
Funding Opportunity RFA-MH-24-150 from the NIH Guide for Grants and Contracts. To use a subset of drug development tools, which are being assessed in the AMP SCZ observational study, in a PoP trial with CHR individuals to determine the ability to detect a biological and/or clinical signal with the compound or compounds selected to use within a 12-16 week study period. The PoP trial will assess the performance of the PSYCHS, other clinical outcome measures, and biological measures. The compound or compounds that are selected for testing in the CHR Clinical Trial Network will affect a pathophysiologically relevant mechan...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 12, 2023 Category: Research Source Type: funding
Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)
Funding Opportunity PAR-24-023 from the NIH Guide for Grants and Contracts. Although the majority living with schizophrenia and related disorders are over 35 years old, including those first diagnosed and those aging with the illness, the mechanisms underlying the generation and trajectory of the illness remain poorly understood. The purpose of this initiative is to advance translational research to better understand the emergence and trajectory of schizophrenia and related disorders in mid to late life, and to identity targets for future development of prevention and treatment efforts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 29, 2023 Category: Research Source Type: funding
Schizophrenia and related disorders during mid- to late-life (R21 Clinical Trial Optional)
Funding Opportunity PAR-24-026 from the NIH Guide for Grants and Contracts. Although the majority living with schizophrenia and related disorders are over 35 years old, including those first diagnosed and those aging with the illness, the mechanisms underlying the generation and trajectory of the illness remain poorly understood. The purpose of this initiative is to advance translational research to better understand the emergence and trajectory of schizophrenia and related disorders in mid to late life, and to identity targets for future development of prevention and treatment efforts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 29, 2023 Category: Research Source Type: funding
Notice of Change in Award Budget for RFA-MH-22-271, "Schizophrenia and related disorders during mid- to late-life (R21 Clinical Trial Optional)"
Notice NOT-MH-23-215 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 14, 2023 Category: Research Source Type: funding
Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)
Funding Opportunity PAR-23-102 from the NIH Guide for Grants and Contracts. Reissue of RFA-MH-21-106 The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 13, 2023 Category: Research Source Type: funding
Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)
Funding Opportunity PAR-23-097 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood and p...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 6, 2023 Category: Research Source Type: funding
Schizophrenia and related disorders during mid- to late-life (R21 Clinical Trial Optional)
Funding Opportunity RFA-MH-22-271 from the NIH Guide for Grants and Contracts. Although the majority living with schizophrenia and related disorders are over 35 years old, including those first diagnosed and those aging with the illness, the mechanisms underlying the generation and trajectory of the illness remain poorly understood. The purpose of this initiative is to advance translational research to better understand the emergence and trajectory of schizophrenia and related disorders in mid to late life, and to identity targets for future development of prevention and treatment efforts (Source: NIH Funding Opportunit...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 19, 2022 Category: Research Source Type: funding
Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)
Funding Opportunity RFA-MH-22-270 from the NIH Guide for Grants and Contracts. Although the majority living with schizophrenia and related disorders are over 35 years old, including those first diagnosed and those aging with the illness, the mechanisms underlying the generation and trajectory of the illness remain poorly understood. The purpose of this initiative is to advance translational research to better understand the emergence and trajectory of schizophrenia and related disorders in mid to late life, and to identity targets for future development of prevention and treatment efforts (Source: NIH Funding Opportunit...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 19, 2022 Category: Research Source Type: funding
Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)
Funding Opportunity PAR-22-035 from the NIH Guide for Grants and Contracts. Reissue of RFA-MH-21-105 The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 20, 2021 Category: Research Source Type: funding
Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)
Funding Opportunity PAR-22-036 from the NIH Guide for Grants and Contracts. Reissue of RFA-MH-21-106 The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 20, 2021 Category: Research Source Type: funding
Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)
Funding Opportunity RFA-MH-21-106 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood an...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 18, 2020 Category: Research Source Type: funding
Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)
Funding Opportunity RFA-MH-21-105 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood an...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 18, 2020 Category: Research Source Type: funding
Reducing the Duration of Untreated Psychosis in the United States (R01 Clinical Trial Required)
Funding Opportunity PAR-19-236 from the NIH Guide for Grants and Contracts. Approximately 100,000 adolescents and young adults in the United States experience a first episode of psychosis (FEP) every year. The early phase of psychotic illness is widely viewed as a critical opportunity for indicated prevention, and a chance to alter the downward trajectory and poor outcomes associated with schizophrenia and related psychotic disorders. Unfortunately, numerous studies find a substantial delay between the onset of psychotic symptoms and the initiation of FEP care; in the U.S. treatment is typically delayed between one and ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 2, 2019 Category: Research Source Type: funding
